Pharmacokinetics and efficacy of Ustekinumab in Crohn's disease

Pharmacokinetics and efficacy of Ustekinumab in Crohn's disease - Efficacy of Ustekinumab in Crohn's disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033552

Enrollment

120

Registered

2018-07-29

Start date

2017-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Crohn's disease patient being treated with Ustekinumab or scheduled for treatment with Ustekinumab

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Clinical remission at 24 weeks and 48 weeks from the start of administration	—

Countries

Japan

Contacts

Public ContactYasuhiro Morita

Shiga University of Medical Science Division of gastroenterology

hqmed2@belle.shiga-med.ac.jp077-548-2111

Outcome results